vs
Side-by-side financial comparison of CRA INTERNATIONAL, INC. (CRAI) and Esperion Therapeutics, Inc. (ESPR). Click either name above to swap in a different company.
CRA INTERNATIONAL, INC. is the larger business by last-quarter revenue ($197.0M vs $168.4M, roughly 1.2× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 11.6%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs 7.1%).
CRA INTERNATIONAL, INC.CRAIEarnings & Financial Report
CRA International, Inc. is a global consulting firm headquartered in Boston. The firm provides expert testimony and litigation support, strategic advice, and analysis to law firms, corporations, accounting firms, and governments.
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
CRAI vs ESPR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $197.0M | $168.4M |
| Net Profit | $13.2M | — |
| Gross Margin | — | — |
| Operating Margin | 10.5% | 50.6% |
| Net Margin | 6.7% | — |
| Revenue YoY | 11.6% | 143.7% |
| Net Profit YoY | -12.0% | — |
| EPS (diluted) | $1.99 | $0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $197.0M | $168.4M | ||
| Q3 25 | $185.9M | $87.3M | ||
| Q2 25 | $186.9M | $82.4M | ||
| Q1 25 | $181.9M | $65.0M | ||
| Q4 24 | $176.4M | $69.1M | ||
| Q3 24 | $167.7M | $51.6M | ||
| Q2 24 | $171.4M | $73.8M | ||
| Q1 24 | $171.8M | $137.7M |
| Q4 25 | $13.2M | — | ||
| Q3 25 | $11.5M | $-31.3M | ||
| Q2 25 | $12.1M | $-12.7M | ||
| Q1 25 | $18.0M | $-40.5M | ||
| Q4 24 | $15.0M | — | ||
| Q3 24 | $11.4M | $-29.5M | ||
| Q2 24 | $6.5M | $-61.9M | ||
| Q1 24 | $13.7M | $61.0M |
| Q4 25 | 10.5% | 50.6% | ||
| Q3 25 | 9.3% | -11.4% | ||
| Q2 25 | 10.6% | 8.6% | ||
| Q1 25 | 14.0% | -34.0% | ||
| Q4 24 | 12.2% | -6.4% | ||
| Q3 24 | 11.0% | -31.0% | ||
| Q2 24 | 6.6% | 3.5% | ||
| Q1 24 | 11.4% | 52.5% |
| Q4 25 | 6.7% | — | ||
| Q3 25 | 6.2% | -35.9% | ||
| Q2 25 | 6.5% | -15.4% | ||
| Q1 25 | 9.9% | -62.2% | ||
| Q4 24 | 8.5% | — | ||
| Q3 24 | 6.8% | -57.2% | ||
| Q2 24 | 3.8% | -83.9% | ||
| Q1 24 | 8.0% | 44.3% |
| Q4 25 | $1.99 | $0.32 | ||
| Q3 25 | — | $-0.16 | ||
| Q2 25 | — | $-0.06 | ||
| Q1 25 | — | $-0.21 | ||
| Q4 24 | — | $-0.14 | ||
| Q3 24 | — | $-0.15 | ||
| Q2 24 | — | $-0.33 | ||
| Q1 24 | — | $0.34 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $18.2M | $167.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $213.6M | $-302.0M |
| Total Assets | $628.9M | $465.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $18.2M | $167.9M | ||
| Q3 25 | $22.5M | $92.4M | ||
| Q2 25 | $19.4M | $86.1M | ||
| Q1 25 | $25.6M | $114.6M | ||
| Q4 24 | $26.7M | $144.8M | ||
| Q3 24 | $24.5M | $144.7M | ||
| Q2 24 | $24.6M | $189.3M | ||
| Q1 24 | $37.1M | $226.6M |
| Q4 25 | $213.6M | $-302.0M | ||
| Q3 25 | $201.7M | $-451.4M | ||
| Q2 25 | $197.0M | $-433.5M | ||
| Q1 25 | $227.3M | $-426.2M | ||
| Q4 24 | $212.1M | $-388.7M | ||
| Q3 24 | $204.5M | $-370.2M | ||
| Q2 24 | $191.7M | $-344.2M | ||
| Q1 24 | $211.8M | $-294.3M |
| Q4 25 | $628.9M | $465.9M | ||
| Q3 25 | $629.0M | $364.0M | ||
| Q2 25 | $606.8M | $347.1M | ||
| Q1 25 | $590.4M | $324.0M | ||
| Q4 24 | $571.4M | $343.8M | ||
| Q3 24 | $582.3M | $314.1M | ||
| Q2 24 | $546.0M | $352.3M | ||
| Q1 24 | $552.5M | $373.1M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $22.4M | $45.2M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | 1.70× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $22.4M | $45.2M | ||
| Q3 25 | $36.5M | $-4.3M | ||
| Q2 25 | $5.9M | $-31.4M | ||
| Q1 25 | $-80.0M | $-22.6M | ||
| Q4 24 | $79.4M | $-35.0M | ||
| Q3 24 | $31.6M | $-35.3M | ||
| Q2 24 | $1.8M | $-7.2M | ||
| Q1 24 | $-63.1M | $53.8M |
| Q4 25 | — | — | ||
| Q3 25 | $35.9M | — | ||
| Q2 25 | $4.7M | — | ||
| Q1 25 | $-81.0M | — | ||
| Q4 24 | $68.8M | — | ||
| Q3 24 | $28.6M | $-35.5M | ||
| Q2 24 | $-509.0K | $-7.3M | ||
| Q1 24 | $-63.8M | $53.8M |
| Q4 25 | — | — | ||
| Q3 25 | 19.3% | — | ||
| Q2 25 | 2.5% | — | ||
| Q1 25 | -44.5% | — | ||
| Q4 24 | 39.0% | — | ||
| Q3 24 | 17.0% | -68.7% | ||
| Q2 24 | -0.3% | -9.9% | ||
| Q1 24 | -37.1% | 39.0% |
| Q4 25 | — | 0.0% | ||
| Q3 25 | 0.3% | 0.0% | ||
| Q2 25 | 0.6% | 0.0% | ||
| Q1 25 | 0.5% | 0.0% | ||
| Q4 24 | 6.0% | 0.0% | ||
| Q3 24 | 1.8% | 0.3% | ||
| Q2 24 | 1.4% | 0.1% | ||
| Q1 24 | 0.4% | 0.1% |
| Q4 25 | 1.70× | — | ||
| Q3 25 | 3.19× | — | ||
| Q2 25 | 0.48× | — | ||
| Q1 25 | -4.44× | — | ||
| Q4 24 | 5.30× | — | ||
| Q3 24 | 2.76× | — | ||
| Q2 24 | 0.28× | — | ||
| Q1 24 | -4.61× | 0.88× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CRAI
Segment breakdown not available.
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
